Shots:
- PerkinElmer to acquire BioLegend for ~$5.25B in cash and stock transaction. The acquisition is expected to close by the end of 2021
- The acquisition will allow PerkinElmer to build its growth in areas such as clinical diagnostics and food safety testing
- With the acquisition, BioLegend’s San Diego, California-based campus will become the global center for the development of chemical reagents used in medical research for the combined company
Click here to read the full press release/ article | Ref: PRNewswire | Image: BioLegend
The post PerkinElmer to Acquire BioLegend for $5.25B first appeared on PharmaShots.
